Results 1 to 10 of about 22,449 (147)

Asymmetric synthesis of (−)-naltrexone

Chemical Science, 2019
The asymmetric synthesis of (−)-naltrexone was achieved by a Rh(i)-catalyzed C–H alkenylation and torquoselective electrocyclization cascade and late-stage C–H hydroxylation.
Sun Dongbang, Blaine Pedersen, Jonathan A. Ellman   +2 more
openaire   +3 more sources

Effectiveness of Alcohol Use Disorder Pharmacotherapies by Sex: Systematic Review and Meta-Analysis. [PDF]

Drug Alcohol Rev
Allen J, Jones A, Shorter GW, Montgomery C, Kougiali Z, Bagnall A, Adshead C, Smith J, Burton S, Atkinson A, Guelen L, Rose A.   +11 more
europepmc   +1 more source

Naltrexone for Acute Management of Compulsive Sexual and Obsessive Symptoms in a Patient With a Neurodevelopmental Disorder. [PDF]

Case Rep Psychiatry
Constantin E, Deol MS, Yaun J, Singh H, Glass OM.   +4 more
europepmc   +1 more source

The Use of Naltrexone to Successfully Treat Severe Hailey-Hailey Disease. [PDF]

Cureus
Mehrabian F, Vaughan E, Abid M, Gandhi N, Hawari R.   +4 more
europepmc   +1 more source

The expanding potential of low-dose naltrexone in clinical practice with a focus on long COVID. [PDF]

Ment Health Clin
Pucci SL, Veide A, Pierce H, Kaminski D.
europepmc   +1 more source

Identifying Predictors of Weight-Related Outcomes With Fixed-Dose, Extended-Release Naltrexone and Bupropion Among Treatment-Adherent Patients in Phase 3 COR Trials: A Treatment Target Analysis. [PDF]

Obes Sci Pract
Ryan DH, Fitch A, Kushner RF, Tronieri JS, Still CD, Apovian CM.   +5 more
europepmc   +1 more source

Effectiveness of Naltrexone and Baclofen Combination in Reducing Craving among Patients with Alcohol Dependence: An Open-label Trial. [PDF]

Clin Psychopharmacol Neurosci
Naqvi A, Nischal A, Singh A, Nischal A.
europepmc   +1 more source

Medicaid Managed Care Plan Alignment With State Substance Use Disorder Treatment Coverage Requirements. [PDF]

Milbank Q
Feltus SR, Andrews CM, Peterson L, Grogan CM, Abraham AJ, Hinds OM, Stewart MT.   +6 more
europepmc   +1 more source

A Membrane-Centric Plasma Lipidomic Signature of Response to Long-Acting Naltrexone in Alcohol Use Disorder. [PDF]

Addict Biol
Huang L, Zhou B, Ou Q, Yin J, Tian X, Zhou X.   +5 more
europepmc   +1 more source

Design of INFORMUS, a pragmatic, randomized, double-blind, placebo-controlled study of cardiovascular outcomes with the extended-release, fixed-dose combination of naltrexone and bupropion. [PDF]

Obes Pillars
Kyle M, Savastano DM, Sharpe TA, Kelly B.   +3 more
europepmc   +1 more source